Jeffrey Eisele - Jan 16, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Stock symbol
APLS
Transactions as of
Jan 16, 2024
Transactions value $
$1,851,470
Form type
4
Date filed
1/17/2024, 12:24 PM
Previous filing
Dec 28, 2023
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +19.5K +36.41% $0.00 73.1K Jan 16, 2024 Direct F1
transaction APLS Common Stock Sale -$29.3K -438 -0.6% $66.81 72.7K Jan 16, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $1.88M +28.4K $66.30 28.4K Jan 16, 2024 Common Stock 28.4K $66.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
F2 This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
F3 This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.